Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Hyaluronidase injections for treatment of symptomatic pansclerotic morphea-induced microstomia.

Abbas LF, Coias J, Jacobe HT, Nijhawan RI.

JAAD Case Rep. 2019 Sep 25;5(10):871-873. doi: 10.1016/j.jdcr.2019.08.004. eCollection 2019 Oct. No abstract available.

2.

Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change.

Teske NM, Jacobe HT.

Br J Dermatol. 2020 Feb;182(2):398-404. doi: 10.1111/bjd.18097. Epub 2019 Aug 14.

PMID:
31049928
3.

Morphea: Current concepts.

Florez-Pollack S, Kunzler E, Jacobe HT.

Clin Dermatol. 2018 Jul - Aug;36(4):475-486. doi: 10.1016/j.clindermatol.2018.04.005. Epub 2018 Apr 10. Review.

PMID:
30047431
4.

Differentiating trigeminal motor neuropathy and progressive hemifacial atrophy.

Condie D, Crowley NJ, Grabell DA, Jacobe HT.

Cutis. 2018 Jan;101(1):E13-E14. No abstract available.

PMID:
29529117
5.

Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.

O'Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-Hackenberg L, Hynan LS, Hosler GA, Jacobe HT.

J Invest Dermatol. 2017 Aug;137(8):1663-1670. doi: 10.1016/j.jid.2017.04.008. Epub 2017 Apr 24.

6.

Phototherapy for sclerosing skin conditions.

Teske NM, Jacobe HT.

Clin Dermatol. 2016 Sep-Oct;34(5):614-22. doi: 10.1016/j.clindermatol.2016.05.012. Epub 2016 May 20. Review.

PMID:
27638441
7.

Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms.

Cao LY, Chung JS, Teshima T, Feigenbaum L, Cruz PD Jr, Jacobe HT, Chong BF, Ariizumi K.

J Invest Dermatol. 2016 Sep;136(9):1801-1810. doi: 10.1016/j.jid.2016.02.816. Epub 2016 May 25.

8.

Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.

Kim A, Marinkovich N, Vasquez R, Jacobe HT.

J Rheumatol. 2014 Jan;41(1):106-12. doi: 10.3899/jrheum.130029. Epub 2013 Dec 1.

9.

Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.

Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85. doi: 10.1002/acr.21687.

10.

14-MHz ultrasonography as an outcome measure in morphea (localized scleroderma).

Nezafati KA, Cayce RL, Susa JS, Setiawan AT, Tirkes T, Bendeck SE, Jacobe HT.

Arch Dermatol. 2011 Sep;147(9):1112-5. doi: 10.1001/archdermatol.2011.243. No abstract available.

PMID:
21931057
11.

A systematic review of morphea treatments and therapeutic algorithm.

Zwischenberger BA, Jacobe HT.

J Am Acad Dermatol. 2011 Nov;65(5):925-41. doi: 10.1016/j.jaad.2010.09.006. Epub 2011 Jun 8. Review.

PMID:
21645943
12.

Activation of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in frequent tanners: a pilot study.

Harrington CR, Beswick TC, Graves M, Jacobe HT, Harris TS, Kourosh S, Devous MD Sr, Adinoff B.

Addict Biol. 2012 May;17(3):680-6. doi: 10.1111/j.1369-1600.2010.00312.x. Epub 2011 Apr 11.

PMID:
21481104
13.

An evaluation of long-term outcomes in adults with pediatric-onset morphea.

Saxton-Daniels S, Jacobe HT.

Arch Dermatol. 2010 Sep;146(9):1044-5. doi: 10.1001/archdermatol.2010.239. No abstract available.

14.

UVA1 phototherapy: a review of mechanism and therapeutic application.

York NR, Jacobe HT.

Int J Dermatol. 2010 Jun;49(6):623-30. doi: 10.1111/j.1365-4632.2009.04427.x. Review.

PMID:
20618465
15.

Addictive-like behaviours to ultraviolet light among frequent indoor tanners.

Harrington CR, Beswick TC, Leitenberger J, Minhajuddin A, Jacobe HT, Adinoff B.

Clin Exp Dermatol. 2011 Jan;36(1):33-8. doi: 10.1111/j.1365-2230.2010.03882.x.

PMID:
20545951
16.

Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases.

Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT.

Arch Dermatol. 2009 May;145(5):545-50. doi: 10.1001/archdermatol.2009.79.

17.

UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V.

Jacobe HT, Cayce R, Nguyen J.

Br J Dermatol. 2008 Sep;159(3):691-6. doi: 10.1111/j.1365-2133.2008.08672.x. Epub 2008 Jun 7.

PMID:
18544076
18.

Photoimmunology--illuminating the immune system through photobiology.

Leitenberger J, Jacobe HT, Cruz PD Jr.

Semin Immunopathol. 2007 Apr;29(1):65-70. Review.

PMID:
17621955
20.

Understanding clinical trial outcomes: design, analysis, and interpretation.

Jacobe HT, Leitenberger JJ, Bergstresser PR.

Dermatol Ther. 2007 Mar-Apr;20(2):77-85.

PMID:
17537135
21.

"Blind man dermatology" revisited.

Bergstresser PR, Jacobe HT.

Dermatol Ther. 2007 Mar-Apr;20(2):75-6. No abstract available.

PMID:
17537134
22.

Argyria secondary to ingestion of homemade silver solution.

Brandt D, Park B, Hoang M, Jacobe HT.

J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S105-7.

PMID:
16021155

Supplemental Content

Loading ...
Support Center